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ABSTRACT 
Polymeric micelles have demonstrated wide utility for chemodrug delivery, which however, still suffer from shortcomings such as undesired 
drug loading, disassembly upon dilution, pre-leakage of drug cargoes during systemic circulation, and lack of cancer-selective drug release. 
Herein, a poly(ethylene glycol) (PEG)-polyphosphoester-based, reactive oxygen species (ROS)-responsive, core-cross-linked (CCL) micellar 
system was developed to encapsulate both chemodrug (doxorubicin, Dox) and photosensitizer (chlorin e6, Ce6). The hydrophobic core of the 
micelles was cross-linked via a thioketal (TK)-containing linker, which notably enhanced the drug loading and micelle stability. In tumor cells, 
far-red light irradiation of Ce6 generated ROS to cleave the TK linkers and disrupt the micelle cores. As such, micelles were destabilized and 
Dox release was promoted, which thereafter imparted synergistic anti-cancer effect with ROS-mediated photodynamic therapy. This study 
provides an effective approach to realize the precise control over drug loading, formulation stability, and cancer-selective drug release using 
polymeric micelles, and would render promising utilities for the programmed anti-cancer combination therapy. 
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Polymeric micelles (PMs) have been extensively used for anticancer 
therapeutic delivery, owing to their desired capabilities to enhance 
the solubility of drugs, prolong blood circulation, improve tumor 
accumulation through the enhanced permeability and retention 
(EPR) effect, and reduce side effects [1–5]. Nevertheless, clinical 
applications of PMs are largely limited by the premature disintegration 
before they reach the tumor sites [6–8]. Additionally, most of the 
therapeutics are loaded in PMs via weak hydrophobic interactions, 
and increasing evidence has suggested that the thermo-dynamic PMs 
could disassemble in the blood circulation because of the extensive 
dilution, and the unexpected drug leakage will occur to cause serious 
side effects [9–11]. Lam et al. found that when the drug loading of 
micelles was lower than 5 wt.%, polymers inside the micelles were 
mostly inter-molecularly overlapped [12]. Thereby the micelles 
possessed suitable and stable sizes to reach the tumor sites through 
the EPR effect. However, when the drug loading was higher than 
5 wt.%, the micelles may re-assemble into bigger micelles with a 
small portion of drugs (< 19%) leaking from the micelles during the 
re-assembly [13]. Therefore, it is highly demanded to stabilize the 
micelle systems while maintaining satisfactory drug loading. 
To increase the stability of PMs and prevent the immature drug 
release, the core-cross-linking strategy has been proposed [14–17]. 
The chemical cross-linking could effectively resist the dilution- 
induced micelle disassembly, and the more compact hydrophobic 
core would afford better drug encapsulation capability. To further 
enable on-demand drug release in cancer tissues/cells, stimuli- 
responsive core-cross-linked (CCL) micelles that can undergo 
selective de-cross-linking upon cancer-specific triggers have been 
investigated for drug delivery. Commonly utilized stimuli include 
pH [18, 19], redox [20], reactive oxygen species (ROS) [21, 22], and 
enzymes [23], etc. However, these triggers often lack cancer selectivity 
(such as pH and redox), have heterogeneous intensity among different 
tumor types, or are not strong enough to provoke pronounced 
responsiveness from the vehicles. For instance, the ROS concentration 
in cancer cells is often insufficient to trigger the transformation of 
ROS-responsive domains, such as thioketal (TK) [24], arylboronic 
acid [25], thioether [26], selenium [27, 28], and tellurium [29, 30]. 
While development of CCL micelles with higher ROS sensitivity 
would be a promising approach, it is chemically challenging to design 
new and ultra-ROS-responsive domain. An alternative approach to 
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address this issue could be manually elevating the ROS levels in 
cancer cells [31, 32], thus magnifying the response of nanovehicles 
to ROS.  
Photodynamic therapy (PDT), involving the production of various 
types of ROS by photosensitizers (PSs) under light activation, is 
regarded as a promising strategy for cancer therapy [33–37]. Compared 
with surgery and chemotherapy, PDT features less invasiveness, 
better tumor localization, and minimal drug resistance [38–40]. 
More importantly, the high levels of ROS generated by PDT can not 
only induce cancer cell apoptosis and necrosis, but can also create 
a specific ROS-rich microenvironment to trigger on-demand 
de-cross-linking of the ROS-responsive CCL micelles to enable 
selective chemodrug release in cancer cells.  
Herein, we report the design of a core-cross-linked, poly(ethylene 
glycol) (PEG)-polyphosphoester-based micellar system for the 
co-delivery of chemodrug (doxorubicin, Dox) and photosensitizer 
(chlorin e6, Ce6). The core of the micelles was stabilized via 
cross-linking by the TK-containing linkers, and the PEG shell could 
stabilize the whole micellar system and enable long circulation in 
the blood. Dox and Ce6 were co-encapsulated into the cross-linked 
hydrophobic core of the CCL micelles, thus preventing premature 
leakage during systemic circulation. Upon reaching the tumor tissues, 
the site-specific far red light irradiation (660 nm, 5 mW/cm2) could 
generate extensive ROS which can break down the TK cross-linker 
to destabilize the micelles and trigger instantaneous Dox release. 
Synergistically, the released Dox and the generated ROS will lead to 
apoptosis and necrosis of the cancer cells (Scheme 1). 
2 Experimental 
2.1 Materials, cells, and animals 
Ce6 was purchased from Frontier Scientific (Newark, USA). 
3-Mercaptopropionic acid, 2-chloroethylamine hydrochloride, o- 
benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate 
(HBTU), 1-hydroxybenzotriazole (HOBt), copper(II) sulfate (CuSO4), 
sodium ascorbate, pentamethyldiethylenetriamine (PMDEM), 
poly(ethylene glycol) methyl ether (PEG-OH) (Mn = 5 kDa), and 
sodium azide were purchased from Energy Chemical (Shanghai, 
China). Dichloromethane (DCM), anhydrous sodium sulfate 
(Na2SO4), anhydrous tetrahydrofuran (THF), diethyl ether (Et2O), 
dimethylformamide (DMF), anhydrous acetone, hydrogen peroxide 
(H2O2), and pyrene were purchased from Sinopharm Chemical 
Reagent Co., Ltd (Shanghai, China). Dox, deuterated chloroform 
(CDCl3), deuterated water (D2O), deuterated dichlorosulfoxide 
(DMSO-d6), and stannous octoate (Sn(Oct)2) were purchased 
from J&K (Shanghai, China). All chemicals were used as received 
unless otherwise indicated. 2-(But-3-yn-1-yloxy)-2-oxo-1,3,2- 
dioxaphospholane (BYP) was synthesized as reported before [41]. 
3-(4,5-Dimethylthiahiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT) was purchased from Invitrogen (Carlsbad, CA, USA). 
4T1 (mouse mammary carcinoma) and MCF-7 (human breast 
adenocarcinoma) cells were purchased from the American Type 
Culture Collection (Rockville, MD, USA). MCF-7 cells were cultured 
in Dulbecco’s modified Eagle medium (DMEM) (Gibco, Grand 
Island, NY, USA) containing 10% fetal bovine serum (FBS). 4T1 
 
Scheme 1 Illustration of ROS-sensitive core-cross-linked PEG-PBYP micelles for synergistic cancer therapy. When the micelles reached the tumor areas through 
EPR effect and then entered the cells via endocytosis, the PS was activated to produce numerous of ROS, triggered decrosslinked of the micelles and speeded drug 
release. 
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cells were cultured in 1640 medium (Gibco, Grand Island, NY, USA) 
containing 10% FBS.  
Female BALB/c mice (6–8 week, 18–20 g) were obtained from 
Shanghai Slaccas Experimental Animal Co., Ltd (Shanghai, China), 
and were housed in an SPF room. The animal experimental protocols 
were approved by the Institutional Animal Care and Use Committee, 
Soochow University. 
2.2 Synthesis and characterization of poly(ethylene glycol)- 
block-poly(2-(but-3-yn-1-yloxy)-2-oxo-1,3,2-dioxaphospholane) 
(PEG-PBYP) 
PEG-PBYP was synthesized via ring-opening polymerization (ROP) 
of BYP as initiated by PEG-OH [42]. Briefly, in a glovebox, BYP 
(105 mg, 0.6 mmol), Sn(Oct)2 (8.1 mg, 0.02 mmol), and PEG-OH 
(100 mg, 0.02 mmol) were dissolved in anhydrous THF (5 mL), and 
the solution was stirred at 40 °C for 24 h. The final product PEG- 
PBYP was obtained as white powder after precipitation with diethyl 
ether/methanol (10:1, v/v). The copolymer structure was characterized 
by 1H NMR, and the molecular weight distribution was determined 
by gel permeation chromatography (GPC) (Table S1 in the Electronic 
Supplementary Material (ESM)). 
2.3 Synthesis and characterization of the TK-containing 
cross-linker 
3-Mercaptopropionic acid (5.2 g, 49.1 mmol) and anhydrous 
acetone (5.8 g, 98.2 mmol) were mixed in a flask under a dry  
HCl atmosphere at room temperature. After 6 h, the mixture was 
crystallized in an ice-salt bath. The crude product was successively 
washed with hexane (3 × 50 mL) and cold water (3 × 50 mL), and 
3,3'-(propane-2,2-diylbis(sulfanediyl))dipropionic acid (compound 1) 
was obtained as white solid (5.5 g, yield 65.2%) [43]. 
Sodium azide (5.85 g, 90 mmol) and 2-chloroethylamine hydro-
chloride (5.22 g, 45 mmol) were dissolved in water (50 mL), and the 
mixture was stirred at 80 °C for 24 h. After the pH was adjusted to 
12 using NaOH solution (1 mol/L), the reaction mixture was 
extracted with Et2O (3 × 50 mL). The organic phase was combined 
and dried over anhydrous Na2SO4. The mixture was filtered and the 
solvent was removed by vacuum. To avoid explosion, a small portion 
of solvent must be left. 3-Azidoethan-1-amine (compound 2) (7.5 g, 
yield 66.7%) was obtained as colorless oil [44].  
Compound 1 (1.05 g, 1 mmol) and compound 2 (8.04 g, 2 mmol) 
were dissolved in dry DMF (30 mL). HBTU (606 mg, 1.6 mmol, 1.6 
eq.) and HOBt (216 mg, 1.6 mmol, 1.6 eq.) dissolved in DMF (10 mL) 
were added. After stirring at room temperature for 24 h, the reaction 
mixture was extracted with Et2O (3 × 100 mL). The organic phase 
was combined and dried over anhydrous Na2SO4 before the solvent 
was removed by vacuum. The crude product was purified by flash 
silica gel column chromatography with DCM/hexane (1/1, v/v) as 
the eluent, and the TK-containing cross-linker (compound 3) was 
obtained as yellow powder [45]. 
The non-responsive cross-linker, 1,6-diazidohexane (compound 4), 
was synthesized using a similar method as described before [46]. 
2.4 Preparation and characterization of micelles  
The ROS-responsive core-cross-linked (RCCL) micelles, non- 
responsive core-cross-linked (NCCL) micelles, and un-cross-linked 
(UCL) micelles were prepared via the nanoprecipitation method 
(Table 1). Taking RCCL micelles as an example, PEG-PBYP 
(10 mg/mL in DMF, 100 μL, 1 eq. of alkyne groups) and compound 
3 (10 mg/mL in DMF, 50 μL) were mixed together, which was added 
dropwisely into deionized water (2 mL) under vigorous stirring. 
After 1 h, CuSO4 (4.1 × 10−3 mmol, 0.25 mol eq. of the alkynyl groups), 
sodium ascorbate (4.1 × 10−3 mmol, 0.25 mol eq. of the alkynyl groups) 
and PMDEM (4.1 × 10−3 μmol, 0.025 μmol eq. of the alkynyl groups) 
were added under the nitrogen atmosphere. After stirring for 24 h, 
the RCCL micelles were obtained followed by dialysis against 
deionized water for 24 h (MWCO = 3.5 kDa). The micelles were 
characterized by dynamic laser scattering (DLS) and transmission 
electron microscopy (TEM). Compound 4 instead of compound 3 
was used to prepare the NCCL micelles using the same method. For 
UCL micelles, PEG-PBYP was nanoprecipitated into deionized water 
in the absence of the crosslinker using the similar method.  
Pyrene was used as the probe to determine the critical micelle 
concentration (CMC) of the polymers [47]. Pyrene dissolved in 
acetone (0.6 mM, 1 mL) was put in the vial, and acetone was removed 
via volatilization. Then UCL micelles with different concentrations 
varied from 6.0 × 10−4 to 0.15 mM were added to the vials under 
stirring. The fluorescence intensity of the solution was recorded 
using a fluorescence spectrometer with the excitation wavelength of 
290–360 nm and the emission wavelength of 390 nm. The cross- 
point of the intensity ratio I372/I383 at the lowest and the highest 
concentration was the CMC of micelles.  
2.5 Stability and ROS-triggered de-crosslinking of RCCL 
micelles 
Sizes of the RCCL, NCCL, and UCL micelles (1 mg/mL in water) after 
dilution with DMF for 10 fold were determined by DLS. To probe 
the ROS-sensitivity, RCCL, NCCL, and UCL micelles (1 mg/mL in 
water) were treated with H2O2 (0.5 mM) for 4 h. Changes of the size 
and morphology were explored by DLS and TEM. The CMC of the 
TK-crosslinked PEG-PBYP after treatment with H2O2 (0.5 mM, 4 h) 
was also determined with the same method as described above. 
2.6 Drug encapsulation and ROS-responsive drug release 
The drug-loaded micelles were prepared using the same method as 
described for the blank micelles, except that the drug cargoes were 
mixed with the polymer and crosslinker before being nanoprecipitated 
into water. For example, in order to prepare Dox and Ce6-co-loaded 
RCCL micelles (RCCL-DC), PEG-PBYP (10 mg/mL in DMF, 100 μL, 
1 eq. of the alkyne groups), compound 3 (10 mg/mL in DMF, 50 μL), 
Dox (5 mg/mL in DMF, 60 μL), and Ce6 (5 mg/mL in DMF, 60 μL) 
were mixed together and the solution was added dropwisely into 
deionized water (3 mL) (theoretical drug loading of both Dox and Ce6 
at 23.1%) under vigorous stirring. After 1 h, CuSO4 (4.1 × 10−3 mmol, 
0.25 eq. of the alkyne groups), sodium ascorbate (4.1 × 10−3 mmol, 
0.25 eq. of the alkyne groups), and PMDEM (4.1 × 10−3 μmol, 0.025 
eq. of the alkyne groups) were added into the solution under nitrogen 
atmosphere. After 24 h, the micelles were obtained and dialyzed 
against deionized water for 24 h (MWCO = 3.5 kDa). The whole 
process was kept in the dark.  
The Dox-loaded RCCL micelles (RCCL-Dox), Ce6-loaded RCCL 
micelles (RCCL-Ce6), and 1,1-dioctadecyl-3,3,3,3-tetramethylindo-
tricarbocyanine iodide (DiR)-loaded RCCL micelles (RCCL-DiR) 
were prepared similarly. The Dox-loaded NCCL micelles (NCCL- 
Dox), Ce6-loaded NCCL micelles (NCCL-Ce6), and Dox- and 
Ce6-co-loaded NCCL micelles (NCCL-DC) were prepared similarly 
expect that the TK-containing cross-linker was replaced by the 
non-responsive cross-linker (compound 4). 
The Dox- and Ce6-co-loaded un-cross-linked micelles (UCL-DC) 
were prepared as follows. PEG-PBYP (10 mg/mL in DMF, 100 μL), 
Dox (5 mg/mL in DMF, 60 μL), and Ce6 (5 mg/mL in DMF, 60 μL) 
were mixed together and the solution was added dropwisely into 
deionized water (3 mL) under vigorous stirring. After 4 h, the micelles 
were obtained and dialyzed against deionized water for 24 h (MWCO = 
3.5 kDa). The whole process was kept in the dark. The DiR-loaded 
UCL micelles (UCL-DiR) were prepared using the same process. 
To determine the drug loading in the micelles, RCCL-DC micelles 
(1 mL) were incubated with H2O2 (0.5 mM) for 4 h. Then, the 
mixture was taken (10 μL), mixed with DMF (990 μL), and kept in 
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the dark for 24 h. The content of Dox and Ce6 in the solution was 
determined by spectrofluorimetry (Dox: λex = 485 nm, λem = 592 
nm, Ce6: λex = 630 nm, λem = 666 nm). Drug loading capacity (DLC) 
and drug loading efficiency (DLE) were calculated according to the 
following formulas 
 
DLC (%) = (weight of loaded drug/total weight of polymer and 
loaded drug) × 100% 
DLE (%) = (weight of loaded drug/weight of feeding drug) × 100% 
 
To explore the ROS-responsive Dox release profiles, RCCL-Dox 
micelles (25 μg Dox/mL and 12.4 μg Ce6/mL, 1 mL) were placed 
in a dialysis bag (MWCO = 3.5 kDa) which was immersed in 
phosphate buffer saline (PBS) (7.4, 25 mL) containing H2O2 at 
various concentrations (0, 0.1, and 0.5 mM) and incubated at 37 °C 
under shaking. At determined time intervals, 2 mL of the release 
medium was withdrawn and refreshed with the same volume of 
release medium. The amount of Dox in the harvested release medium 
was determined by spectrofluorimetry (λex = 485 nm, λem = 592 nm). 
The light-triggered Dox release from RCCL-DC micelles was 
further explored. RCCL-DC micelles (25 μg Dox/mL and 12.4 μg 
Ce6/mL, 1 mL) were placed in a dialysis bag (MWCO = 3.5 kDa) 
and irradiated (660 nm, 5 mW/cm2) for 0.5 h. The dialysis bag was 
then immersed in PBS (7.4, 25 mL) and incubated at 37 °C under 
shaking. The amount of Dox released at pre-determined time 
intervals was determined as described above. 
2.7 Detection of light-mediated intracellular ROS production 
Light-induced ROS generation in 4T1 cells was detected using a 
ROS probe, 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA). 
Cells were seeded in a 24-well plate at 3 × 104 cells/well and cultured 
for 24 h. RCCL-Ce6 micelles were added (1 μg Ce6/mL). After 
incubation for 4 h, the DCFH-DA solution was added (10 μM) and 
incubated with cells for another 20 min. The culture medium was 
replaced with fresh medium and irradiated (660 nm, 5 mW/cm2) for 
0.5 h. Cells were then fixed with paraformaldehyde (4%), stained with 
4',6-diamidino-2-phenylindole (DAPI) (5 μg/mL), and observed by 
confocal laser scanning microscopy (CLSM). 
2.8 In vitro cellular uptake 
Briefly, 4T1 cells were seeded on 24-well plates (3 × 104 cells/well) 
and cultured for 24 h. The medium was replaced with fresh medium, 
into which UCL-DC, NCCL-DC, or RCCL-DC micelles were added 
at the final Dox concentration of 1 μg/mL and Ce6 concentration of 
0.5 μg/mL. After incubation for 8 or 12 h, cells were fixed with 4% 
paraformaldehyde, stained with DAPI (5 μg/mL), and observed by 
CLSM. Alternatively, cells were treated with UCL-DC, RCCL-DC, 
and NCCL-DC micelles for 8 h, irradiated (660 nm, 5 mW/cm2) for 
0.5 h, and further incubated for 4 h before CLSM. To quantify the 
cellular uptake level, cells treated as described above were collected, 
resuspended in PBS, and subjected to flow cytometry analysis. 
2.9 In vitro antitumor efficacy 
The in vitro antitumor activity of the drug-loaded micelles was 
evaluated in 4T1 and MCF-7 cells. Briefly, cells were seeded in a 
96-well plate at 7 × 103 cells/well and incubated for 24 h. The medium 
was replaced with fresh medium (90 μL), into which various micelles 
(RCCL-Dox, RCCL-Ce6, RCCL-DC, and NCCL-DC, 10 μL) were 
added at various final Dox equivalent concentrations. After incu-
bation for 8 h, cells treated with RCCL-DC, RCCL-Ce6, and 
NCCL-DC micelles were irradiated (660 nm, 5 mW/cm2) for 0.5 h. 
After incubation for another 48 h, the cell viability was determined 
using the MTT assay.  
A live/dead double-staining assay was adopted to assess the 
cytotoxicity. 4T1 cells were seed on 24-well plates (3 × 104 cells/well), 
cultured for 24 h, treated with free Dox or various micelles at 2 μg 
Dox equivalent/mL for 8 h, irradiated (660 nm, 5 mW/cm2) for 0.5 h, 
and further incubated for 48 h. Cells were then stained with calcein- 
acetoxymethyl ester (calcein-AM) (2 μM, for live cells) and propidium 
iodide (PI, 4.5 μM, for dead cells) for 15 min before observation by 
CLSM. 
The cell apoptosis induced by drug-loaded micelles was further 
evaluated. 4T1 cells were seed on 6-well plates (3 × 106 cells/well) 
and treated with Dox or various micelles as described above. Cells 
were collected, stained using the Annexin V-FITC/PI kit (Beyotime, 
Shanghai, China), and subjected to flow cytometry analysis. 
2.10 Pharmacokinetics and biodistribution 
RCCL-DiR micelles, UCL-DiR micelles, or free DiR were i.v. injected 
to female BALB/c mice at 5.0 mg DiR/kg. At predetermined time 
points, blood (50 μL) was collected from the orbit and mixed with 
Triton X-100 (1%, 600 μL). DiR in the blood was extracted with 
HCl (1% in isopropyl alcohol, 900 μL), and the DiR content was 
determined by spectrofluorimetry (λex = 748 nm, λem = 780 nm). 
The half-life time (t1/2) of the micelles was calculated according to 
the previously reported method [48]. 
For the biodistribution study, 4T1 cells (2.5 × 106) were s.c. injected 
into the right flank of female BALB/c mice. When the tumor reached 
~ 200 mm3, RCCL-DiR micelles, UCL-DiR micelles, and free DiR 
were i.v. injected at 5.0 mg DiR/kg. Live animal fluorescence imaging 
was performed at predetermined time intervals (4, 6, 12, and 24 h 
post-injection) using a Maestro living imaging system (Cambridge 
Research and Instrumentation, Inc.). In another parallel study, mice 
were sacrificed at 12 h post injection, and the major organs (heart, 
liver, spleen, lung, and kidney) as well as tumors were collected and 
imaged. The relative fluorescence intensity of DiR in each tissue 
was quantified (λex = 748 nm, λem = 780 nm). 
2.11 In vivo antitumor efficacy 
4T1 xenograft tumor-bearing mice as described above were used to 
evaluate the in vivo anticancer efficacy of drug-loaded micelles. When 
the tumor volume reached 50–60 mm3, mice were randomly divided 
into six groups (eight mice per group), and they were i.v. injected 
with PBS, free Dox, RCCL-Dox, RCCL-Ce6, RCCL-DC, and UCCL- 
DC micelles on day 1, 4, and 7. The Dox and Ce6 doses for micelles 
were 10 and 4 mg/kg, respectively, while the dose for free Dox was 
5 mg/kg. For RCCL-Ce6, RCCL-DC, and UCCL-DC micelles, the 
tumor sites were irradiated (660 nm, 5 mW/cm2) for 0.5 h at 12 h 
post injection. The tumor volume and body weight were measured 
every other day. The tumor volume was calculated according to 
the following formula: (V = length × width × width/2). Mice with 
tumors larger than 1,000 mm3 should be euthanized according to 
the standard animal protocol. Thus, on day 16, mice were sacrificed, 
and major organs as well as tumors were harvested, fixed with 10% 
formalin, embedded in paraffin, and sectioned. The tissue sections 
were stained with hematoxylin and eosin (H&E) for histological 
evaluation. The tumor tissues were also embedded in optimal cutting 
temperature (OCT) compound, frozen, and cryo-sectioned. The 
tumor sections were stained using the One Step TUNEL Apoptosis 
Assay kit (Beyotime Biotechnology) to evaluate tumor cell apoptosis. 
2.12 Statistical analysis 
Statistical analysis was performed using Student’s t-test. The differences 
between two groups were determined to be significant at *p < 0.05 
and very significant at **p < 0.01 and ***p < 0.001. 
3 Results and discussion 
3.1 Synthesis and characterization of PEG-PBYP copolymers 
The PEG-PBYP polymer was synthesized via the ring-opening 
polymerization of BYP using PEG-OH as the macro-initiator and 
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Sn(Oct)2 as the catalyst (Scheme S1 in the ESM). The polyphosphoester 
was selected as the backbone owing to its biocompatibility, bio-
degradability, and amenability for post-functionalization [49]. 1H 
NMR analysis confirmed the successful synthesis of PEG-PBYP 
(Fig. S1 in the ESM), and the degree of polymerization (DP) of PBYP 
was calculated to be 28 by comparing the peak intensities of the 
methylene protons of PEG (δ, 3.70 ppm) and the alkynyl protons of 
BYP (δ, 2.5 ppm). The molecular weight (MW) and polydispersity 
index (PDI) of the PEG-PBYP polymer were determined to be 11.3 kDa 
and 1.20 by GPC, respectively (Table S1 in the ESM). Both the ROS- 
responsive, TK-containing cross-linker and the non-responsive cross- 
linker were synthesized accordingly (Scheme S1 in the ESM), and 
their structures were confirmed by 1H NMR (Figs. S2–S5 in the ESM). 
3.2 Characterization and ROS-sensitivity of the RCCL 
micelles  
The micelles were prepared using the nanoprecipitation method, 
and they were chemically cross-linked to form CCL micelles. Sizes 
of the UCL, RCCL and NCCL micelles were determined to be 
around 91.5, 64.2, and 63.5 nm by DLS, respectively, with a narrow 
distribution (Fig. 1(a)). The reduced diameter of micelles after 
cross-linking could be attributed to the chemical cross-linking of 
the hydrophobic segment that rendered the micelle cores more 
compact. TEM images revealed spherical structures of the micelles, 
and revealed a more compact core of CCL micelles than the UCL 
micelles, as evidenced by the darkness in TEM images (Fig. 1(d)). 
Upon dilution with DMF for 10 fold, UCL micelle showed no DLS 
signals, indicating complete dissolution and dissociation of the 
micelles (Fig. 1(b)). In comparison, sizes of the NCCL and RCCL 
micelles slightly increased, presumably owing to the swelling of 
micelle cores. These results confirmed the stability of CCL micelles 
in organic solvents due to the core cross-linking via covalent bonding. 
Additionally, the stability of the micelles in different media was 
evaluated over storage for one week. CCL micelles maintained constant  
 
Figure 1 Stability and ROS responsiveness of RCCL micelles. Size of micelles 
in water (a), after dilution with DMF for 10 fold (b), and after treatment with 
0.5 mM H2O2 (c). (d) TEM images of the micelles before and after H2O2 treatment 
(0.5 mM). CMC values of untreated UCL micelles (e) and RCCL micelles treated 
with 0.5 mM H2O2 (f). 
diameters in water (H2O), PBS, cell growth medium (1640 medium), 
and 10% FBS (Fig. S6 in the ESM). However, UCL micelles lacking 
a stable core-cross-linked structure showed significantly increased 
diameters that indicated aggregation (Fig. S6 in the ESM). After 
treatment with H2O2, the diameter of RCCL micelles increased to 
~ 94 nm (Figs. 1(c) and 1(d)), indicating cleavage of the TK linker 
and loosening of the micelle core. As a control, NCCL and UCL 
micelles with no H2O2 responsiveness maintained constant diameters 
and unaltered morphologies (Figs. 1(c) and 1(d)). Furthermore, the 
similar CMC values of UCL micelles (11.8 μg/mL) and H2O2-treated 
RCCL micelles (11.2 μg/mL) confirmed the cleavage of TK linkers 
and de-cross-linking of the RCCL micelles (Figs. 1(e) and 1(f)). 
3.3 Drug loading and in vitro release 
PEG-PBYP polymers could self-assemble into micelles and encap-
sulate Dox and Ce6 in the cores via hydrophobic interactions. 
Drug-loaded UCL micelles (UCL-DC) showed large diameter of 
171.2 nm with a wide distribution (Fig. 2(a)). In comparison, the 
cross-linked RCCL-DC micelles possessed notably smaller diameter 
of 84.5 nm, as confirmed by DLS analysis and TEM observation 
(Figs. 2(a) and 2(b)). DLC of Dox and Ce6 in the UCL-DC micelles 
was relatively low (4.1% and 0.9% for Dox and Ce6, respectively), 
while remarkably higher DLC was noted for the CCL micelles (12% 
and 4%–5% for Dox and Ce6, respectively), 3–5 fold higher than 
the ULC micelles (Table 2). It therefore demonstrated that the core 
cross-linking would benefit the drug encapsulation due to formation 
of a more compact hydrophobic core. When both Dox and Ce6 
were encapsulated in the micelles, the DLE was slightly lower than 
that for the single drug-loaded micelles (Table 2). This may be due 
to the electrostatic repulsion between the polymer backbones and 
the Ce6 molecules that impeded successful encapsulation into the 
hydrophobic core. 
The drug release from micelles was explored to verify the stability 
and responsiveness of the RCCL micelles both in the absence and 
presence of H2O2 (0.1 and 0.5 mM), a representative category of 
ROS. The RCCL-Dox micelles exhibited an H2O2 concentration- 
dependent drug release profile. In the absence of H2O2, the drug 
release from the RCCL-Dox micelles was quite slow with the 
cumulative release amount of ~ 30% within 36 h. In the presence of  
 
Figure 2 Drug loading and release from the micelles. (a) The size distribution 
of UCL-DC, RCCL-DC, and NCCL-DC micelles as measured by DLS. (b) 
Representative TEM images of the drug-loaded micelles. (c) Cumulative Dox 
release from NCCL-Dox and RCCL-Dox micelles in the presence and absence 
of H2O2 (n = 3). (d) Cumulative Dox release from RCCL-DC micelles with or 
without 0.5-h light irradiation (660 nm, 5 mW/cm2) (n = 3).  
 Nano Res. 2019, 12(5): 999–1008 
 | www.editorialmanager.com/nare/default.asp 
1004 
Table 1 Abbreviations of micelles 
Abbreviation Full name 
UCL Un-cross-linked micelles 
CCL Core-cross-linked micelles 
RCCL ROS-responsive core-cross-linked micelles 
NCCL Non-responsive core-cross-linked micelles 
RCCL-Dox Dox-loaded RCCL micelles 
RCCL-Ce6 Ce6-loaded RCCL micelles 
RCCL-DC Dox- and Ce6-co-loaded RCCL micelles 
RCCL-DiR DiR-loaded RCCL micelles 
UCL-DC Dox- and Ce6-co-loaded UCL micelles 
UCL-DiR DiR-loaded UCL micelles 
NCCL-Dox Dox-loaded NCCL micelles 
NCCL-Ce6 Ce6-loaded UCCL micelles 
NCCL-DC Dox- and Ce6-co-loaded NCCL micelles 
Table 2 Characterization of drug-loaded micelles 
Dox Ce6 
Micelle 
DLE (%) DLC (%) DLE (%) DLC (%) 
RCCL-Dox 89.6 15.2 — — 
RCCL-Ce6 — — 32.5 6.1 
RCCL-DC 84.9 12.4 30.5 4.9 
NCCL-DC 84.2 12.3 25.6 4.0 
UCL-DC 14.3 4.1 3.3 0.9 
 
0.1 mM H2O2 (intracellular concentration in cancer cells) [24], drug 
release was slightly accelerated, indicating that the intracellular ROS 
was unable to efficiently trigger the de-crosslinking of micelles 
and drug release (Fig. 2(c)). Comparatively, at elevated H2O2 con-
centration (0.5 mM), pronounced drug release was noted, conferring 
a cumulative release amount of 80% within 36 h. As a non-responsive 
analogue, NCCL-Dox micelles showed unaltered release profile in 
the presence of 0.5 mM H2O2. Such observation therefore suggested 
the feasibility to enhance ROS concentration in cancer cells using 
PDT and accordingly accelerate drug release in response to ROS. In 
support of such hypothesis, more than 80% of the loaded Dox was 
released from RCCL-DC micelles within 4 h after light irradiation 
(Fig. 2(d)), indicating that the loaded PS can efficiently produce ROS 
to break down the TK cross-linker and promote micelle destabilization. 
Taken together, the introduction of TK cross-linker could not 
only increase the stability and the drug loading of the micelles, but 
also provide the micelles with the possibility of on-demand and 
instantaneous drug release upon external light triggers. 
3.4 Intracellular ROS production 
The light-induced ROS production in 4T1 cells was probed using 
a ROS probe, DCFH-DA. The non-fluorescent DCFH-DA can be 
oxidized to fluorescent dichlorofluorescein (DCF) by cellular 
ROS. After 0.5-h light irradiation (660 nm, 5 mW/cm2), the DCF 
fluorescence (green) in cells treated with RCCL-Ce6 micelles 
enhanced significantly, demonstrating sufficient ROS production. 
However, cells treated with PBS or RCCL-Ce6 micelles without light 
activation exhibited weak fluorescence signal (Fig. S7 in the ESM). 
Addition of Vc, an antioxidant to deplete ROS, to the cells before 
light irradiation could remarkably attenuate the DCF fluorescence 
intensity in the cells. The results substantiated the enhanced 
intracellular ROS level induced by light activation of Ce6. 
3.5 In vitro cellular uptake 
The cellular uptake and intracellular distribution of micelles were 
evaluated in 4T1 cells by CLSM and flow cytometry. As shown in 
Fig. 3(a), more red fluorescence signal was detected in the cells 
treated with UCL-Dox micelles than those treated with RCCL-Dox 
or NCCL-Dox micelles for either 8 or 12 h (Figs. 3(a) and 3(b)). The 
same trend was observed for the flow cytometry analysis and the 
quantified fluorescence intensity (Figs. 3(e)–3(g)). Such discrepancy 
was probably because UCL-Dox micelles released Dox faster than 
the CCL micelles, and the fluorescence of the encapsulated Dox in 
the micelles core could be partially quenched [48]. Nevertheless, 
when light irradiation (606 nm, 5 mW/cm2, 0.5 h) was performed 
at 8 h post incubation with micelles followed by incubation for 
another 4 h, the RCCL-DC micelles exhibited comparable intracellular 
fluorescence intensity to the UCL micelles, notably outperforming 
the NCCL-DC micelles (Figs. 3(c), 3(h), and 3(i)), These results thus 
suggested the efficient drug release from RCCL-DC micelles upon 
light-induced ROS generation. 
3.6 In vitro anti-cancer efficacy 
The cytotoxicity of the blank micelles was first investigated using 
the MTT assay. The viability of both 4T1 and MCF-7 cells remained 
above 90% after incubation with micelles at the concentration range 
from 1 to 500 μg/mL, indicating low toxicity of the drug carrier (Fig. 
S8 in the ESM). Then the anti-cancer efficacy of the drug-loaded 
micelles was evaluated using the same cell lines. As shown in 
Figs. 4(a) and 4(b), RCCL-DC micelles exhibited significantly stronger  
 
Figure 3 Cellular uptake and intracellular distribution of micelles. (a)–(c) 
Representative CLSM images of 4T1 cells following incubation with different 
micelles for 8 or 12 h. Scale bar = 50 μm. Flow cytometry analysis of the intra-
cellular Dox content after treatment with different micelles for 8 h (d) and (e), 
12 h without irradiation (f) and (g), and 12 h with irradiation (h) and (i). Light 
irradiation (660 nm, 5 mW/cm2, 0.5 h) was performed after 8-h incubation with 
micelles (n = 3). 
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Figure 4 In vitro anti-tumor efficacy of micelles. Viability of 4T1 (a) and 
MCF-7 (b) cells after treatment with different micelles. IC50 of Dox and Ce6 in 
4T1 (c) and MCF-7 (d) cells after treatment with different micelles. (e) Flow 
cytometric analysis of 4T1 cells treated with different micelles and stained with 
Annexin V-FITC/PI. (f) CLSM images of 4T1 cells treated with different micelles 
and double-stained with calcein-AM (green, live cells) and PI (red, dead cells). 
Scale bar = 100 μm. For all the experiments, cells were incubated with micelles 
for 8 h, irradiated (660 nm, 5 mW/cm2) for 0.5 h, and incubated for an additional 
48 h before the assessments. 
anticancer efficacy than RCCL-Dox micelles (Dox only), RCCL-Ce6 
micelles (Ce6 only), and NCCL-DC micelles (non-responsive) after 
30-min light irradiation. The half-maximal inhibitory concentration 
(IC50) of Dox in RCCL-DC micelles (0.62 μg/mL for 4T1 cells  
and 0.42 μg/mL for MCF-7 cells) was 3–4-fold lower than that in 
RCCL-Dox micelles (2.8 μg/mL for 4T1 cells and 1.6 μg/mL for 
MCF-7 cells). The combination index (CI) between Dox and Ce6 in 
RCCL-DC micelles was far below 1 (0.60 in 4T1 cells and 0.75 in 
MCF-7 cells) (Figs. 4(c) and 4(d)), substantiating the synergistic 
effect between Dox and Ce6 as a result of the light activated, 
PS-mediated ROS generation and subsequent ROS-triggered fast 
Dox release in cancer cells [50].  
Additionally, the potency of the drug-loaded micelles to induce 
cancer cell apoptosis was measured using the Annexin V-FITC/PI 
assay. As shown in Fig. 4(e), the apoptosis rates induced by RCCL- 
Dox, RCCL-Ce6, and NCCL-DC micelles were 30.23%, 51.26%, 
and 53.08%, respectively. In contrast, RCCL-DC micelles induced 
significantly augmented apoptosis rate of 92.40%, which accorded 
well with their anti-cancer efficacy as demonstrated by the MTT 
assay (Fig. 4(a)). 
CLSM images were used to visualize both the dead and live cells 
after treatments, using the calcein-AM and PI double staining assay 
(Fig. 4(f)). Live cells enzymatically hydrolyze the non-fluorescent 
calcein-AM to the green fluorescent calcein, while the PI molecule 
can penetrate the cell membrane of dead cells and bind to DNA  
to emit red fluorescence [51]. Compared with cells treated with 
RCCL-Dox, RCCL-Ce6, and NCCL-DC micelles, cells treated with 
RCCL-DC micelles showed the highest density of red fluorescence, 
indicating their strongest cancer cell killing efficiency (Fig. 4(f)). 
3.7 Pharmacokinetics and biodistribution 
As shown in Fig. 5(a), RCCL-DiR micelles exhibited prolonged blood 
circulation time than free DiR and UCL-DiR micelles after i.v. 
injection, and the half-life (t1/2) of the RCCL-DiR micelles was 5.3 h, 
2.1- and 10.6-fold longer than UCL-DiR micelles (2.5 h) and free 
DiR (0.5 h), respectively. Such prolonged blood circulation time of 
RCCL micelles may be attributed to the stealth property of the PEG 
shells and the stable core-cross-linked structures of the CCL micelles 
that prevented dissociation and pre-leakage of the drug cargoes 
upon extensive dilution by the blood. The biodistribution of micelles 
was further assessed in 4T1 xenograft tumor-bearing mice. As shown 
in Fig. 5(b), RCCL-DiR micelles showed notably stronger fluorescence  
 
Figure 5 Pharmacokinetics and biodistribution of micelles. (a) Pharmacokinetics 
of RCCL-DiR micelles, UCL-DiR micelles, and free DiR following i.v. injection 
(n = 3). (b) Fluorescence imaging of 4T1 tumor-bearing mice at different time 
post i.v. injection of RCCL-DiR micelles, UCL-DiR micelles, and free DiR. 
(c) Ex vivo fluorescence imaging of excised tumors and major organs at 12 h 
post i.v. injection (H: heart; LI: liver; SP: spleen; LU: lung; K: kidney; T: tumor). 
(d) Biodistribution levels of DiR in tumors and major organs at 12 h post i.v. 
injection (n = 3). 
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intensity of DiR in the tumors than free DiR and UCL-DiR micelles, 
and the fluorescence intensity peaked at 12 h post injection. After 
injection, most of the free DiR was accumulated and trapped in 
livers, and UCL-DiR micelles also showed a progressive accumulation 
in livers owing to the undesired stability of the micelles (Fig. 5(b)). 
Notably, the RCCL micelles showed pronounced passive targeting 
to tumor sites mainly ascribed to the prolonged systemic circulation 
and the EPR effect. Then, the major organs and tumors were 
harvested at 12 h post injection, and the ex vivo fluorescence 
intensity further quantified (Figs. 5(c) and 5(d)). The DiR content 
in the tumors treated with RCCL-DiR micelles was 8- and 2-fold 
higher than those of DiR- and UCL-DiR micelles-treated tumors, 
respectively. Taken together, these findings demonstrated the 
advantage of the RCCL micelles with chemically-stabilized structure 
to enable prolonged blood circulation and enhanced tumor 
accumulation following i.v. injection. 
3.8 In vivo antitumor efficacy 
A 4T1 xenograft tumor-bearing murine model was used to evaluate 
the anticancer efficacy of the micelles. The mice were i.v. injected 
with PBS, free Dox (5 mg/kg), RCCL-Dox (10 mg Dox/kg), RCCL- 
Ce6 (4 mg Ce6/kg), NCCL-DC (10 mg Dox/kg, 4 mg Ce6/kg), and 
RCCL-DC (10 mg Dox/kg, 4 mg Ce6/kg). Free Dox was injected 
at 5 mg/kg due to its serious heart toxicity [50]. Based on the 
biodistribution results, 30-min light irradiation was applied at 12 h 
post injection. As indicated in Figs. 6(a) and 6(b), the tumors after 
treatment with PBS grew rapidly and reached the size around 
1,200 mm3 within 16 days. Free Dox and RCCL-Dox showed similar 
and weak tumor inhibition efficacy. RCCL-Ce6 and NCCL-DC  
 
Figure 6 Anti-tumor efficacy of drug-loaded micelles in 4T1 tumor-bearing 
mice. Tumor volume (a) and body weight (b) of mice during the 16-day obser-
vation period. (c) Representative images of tumors on day 16 (b). (d) Survival 
rate of mice within the 40-day observation period. (e) H&E-stained tumor tissues 
on day 16. Scale bar = 100 μm. (f) Cell apoptosis in tumor tissues harvested on 
day 16 as determined by TUNEL staining. Scale bar = 100 μm. Mice were i.v. 
injected with PBS, free Dox, RCCL-Dox micelles, RCCL-Ce6 micelles, NCC-DC 
micelles, and RCCL-DC micelles on day 1, 4 and 7 (4 mg Ce6/kg and 10 mg 
Dox,/kg for micelles, 5 mg/kg for free Dox) (n = 8). Tumor sites were irradiated 
(660 nm, 5 mW/cm2) for 0.5 h at 12 h post injection of micelles. 
micelles showed a stronger inhibition rate of tumor growth compared 
to free Dox, which could be due to the photodynamic effect of the 
encapsulated Ce6. Importantly, the RCCL-DC micelles, upon light 
activation, completely suppressed the growth of solid tumors within 
the 16-day observation period. Among all the treatments, free Dox 
showed remarkable side effect as evidenced by a ~ 10% reduction of 
the body weight (Fig. 6(c)), while negligible body weight loss was 
noted for all test micelles. In accordance with the tumor inhibition 
capability, the RCCL-DC micelles significantly enhanced the survival 
rate of the tumor-bearing mice over the 40-day observation period 
(Fig. 6(d)). Additionally, tumors treated with RCCL-DC micelles 
exhibited the highest tumor cell remission rate in H&E-stained 
tumor tissues (Fig. 6(e)) and the highest tumor cell apoptosis rate 
after TUNEL staining (Fig. 6(f)). Histological observation on major 
organs revealed lack of pathological abnormalities following treat-
ment with RCCL-DC micelles (Fig. S9 in the ESM). These results 
collectively demonstrated the effective and synergistic anti-cancer 
effect of the RCCL micelles, which would undergo ROS-induced 
destabilization upon light irradiation to accelerate Dox release and 
thereby enabling potent and synergistic anti-cancer efficacy with 
negligible side toxicity to normal tissues. 
4 Conclusions 
In summary, we developed a ROS-responsive CCL micellar system 
to enhance the circulation stability and allow on-demand chemodrug 
release via PS-induced ROS generation upon far red light irradiation. 
The RCCL micelles were core-cross-linked via a TK-containing 
linker, which efficiently stabilized the micelles, enhanced the loading 
capacity for Dox and Ce6, and prevented the pre-leakage of drug 
cargoes upon dilution. In the tumor tissues, the loaded Ce6 in 
RCCL-DC micelles produced extensive ROS under light activation 
to cleave the TK linkers and disrupt the micelle cores. As such, 
micelles were destabilized to accelerate Dox release, thereby 
provoking synergistic anti-cancer effect with ROS-mediated photo-
dynamic therapy. This study provides an effective strategy to resolve 
the dilemma of formulation stability and effective as well as cancer- 
selective drug release, and would thus render a promising modality 
for the anti-cancer combination therapy. 
Acknowledgements 
This work was supported by the National Natural Science Foundation 
of China (Nos. 51722305, 51573123, and 51873142), the Ministry 
of Science and Technology of China (No. 2016YFA0201200), the 
111 Project, and Priority Academic Program Development of Jiangsu 
Higher Education Institutions (PAPD). 
 
Electronic Supplementary Material: Supplementary material (the 
synthetic routes of PEG-PBYP, 1H NMR spectra, size variations of 
micelles, cytotoxicity, tissue histology, etc.) is available in the online 
version of this article at https://doi.org/10.1007/s12274-019-2330-y. 
 
Open Access: This article is licensed under a Creative Commons 
Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, 
as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and 
indicate if changes were made.  
The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included 
in the article’s Creative Commons licence and your intended use is 
not permitted by statutory regulation or exceeds the permitted use, 
you will need to obtain permission directly from the copyright 
holder.  
Nano Res. 2019, 12(5): 999–1008 
www.theNanoResearch.com∣www.Springer.com/journal/12274 | Nano Research 
1007 
To view a copy of this licence, visit http://creativecommons.org/ 
licenses/by/4.0/. 
References 
[1] Wicki, A.; Witzigmann, D.; Balasubramanian, V.; Huwyler, J. Nanomedicine 
in cancer therapy: Challenges, opportunities, and clinical applications. 
J. Control. Release 2015, 200, 138–157.  
[2] Kwon, G. S.; Okano, T. Polymeric micelles as new drug carriers. Adv. 
Drug Deliv. Rev. 1996, 21, 107–116.  
[3] Kataoka, K.; Harada, A.; Nagasaki, Y. Block copolymer micelles for drug 
delivery: Design, characterization and biological significance. Adv. Drug 
Deliv. Rev. 2012, 64, 37–48.  
[4] Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Dis. 
2003, 2, 347–360.  
[5] Aouameur, D.; Cheng, H.; Opoku-Damoah, Y.; Sun, B.; Dong, Q. L.; Han, 
Y.; Zhou, J. P.; Ding, Y. Stimuli-responsive gel-micelles with flexible 
modulation of drug release for maximized antitumor efficacy. Nano Res. 
2018, 11, 4245–4264.  
[6] Stuart, M. A. C.; Huck, W. T. S.; Genzer, J.; Müller, M.; Ober, C.; Stamm, 
M.; Sukhorukov, G. B.; Szleifer, I.; Tsukruk, V. V.; Urban, M. et al. Emerging 
applications of stimuli-responsive polymer materials. Nat. Mater. 2010, 9, 
101–113.  
[7] Cao, Z. Y.; Ma, Y. C.; Sun, C. Y.; Lu, Z. D.; Yao, Z. Y.; Wang, J. X.; Li, D. 
D.; Yuan, Y. Y.; Yang, X. Z. ROS-sensitive polymeric nanocarriers with 
red light-activated size shrinkage for remotely controlled drug release. 
Chem. Mater. 2017, 30, 517–525.  
[8] Ding, D.; Zhu, Z. S.; Li, R. T.; Li, X. L.; Wu, W.; Jiang, X. Q.; Liu, B. R. 
Nanospheres-incorporated implantable hydrogel as a trans-tissue drug 
delivery system. ACS Nano 2011, 5, 2520–2534.  
[9] Phelps, E. A.; Enemchukwu, N. O.; Fiore, V. F.; Sy, J. C.; Murthy, N.; 
Sulchek, T. A.; Barker, T. H.; García, A. J. Maleimide cross-linked bioactive 
peg hydrogel exhibits improved reaction kinetics and cross-linking for cell 
encapsulation and in situ delivery. Adv. Mater. 2012, 24, 64–70.  
[10] Wang, P .; Wang, J. X.; Tan, H. W.; Weng, S. F.; Cheng, L. Y.; Zhou, Z. P.; 
Wen, S. Acid- and reduction-sensitive micelles for improving the drug 
delivery efficacy for pancreatic cancer therapy. Biomater. Sci. 2018, 6, 
1262–1270. 
[11] Shuai, X. T.; Merdan, T.; Schaper, A. K.; Xi, F.; Kissel, T. Core-cross-linked 
polymeric micelles as paclitaxel carriers. Bioconjugate Chem. 2004, 15, 
441–448.  
[12] Talelli, M.; Barz, M.; Rijcken, C. J. F.; Kiessling, F.; Hennink, W. E.; 
Lammers, T. Core-crosslinked polymeric micelles: Principles, preparation, 
biomedical applications and clinical translation. Nano Today 2015, 10, 
93–117.  
[13] Li, Y. P.; Xiao, K.; Luo, J. T.; Xiao, W. W.; Lee, J. S.; Gonik, A. M.; Kato, 
J.; Dong, T. A.; Lam, K. S. Well-defined, reversible disulfide cross-linked 
micelles for on-demand paclitaxel delivery. Biomaterials 2011, 32, 
6633–6645.  
[14] Gulfam, M.; Matini, T.; Monteiro, P. F.; Riva, R.; Collins, H.; Spriggs, K.; 
Howdle, S. M.; Jérôme, C.; Alexander, C. Bioreducible cross-linked core 
polymer micelles enhance in vitro activity of methotrexate in breast cancer 
cells. Biomater. Sci. 2017, 5, 532–550.  
[15] Pitarresi, G.; Casadei, M. A.; Mandracchia, D.; Paolicelli, P.; Palumbo, F. 
S.; Giammona, G. Photocrosslinking of dextran and polyaspartamide 
derivatives: A combination suitable for colon-specific drug delivery. J. 
Control. Release 2007, 119, 328–338.  
[16] Ding, J. X.; Zhuang, X. L.; Xiao, C. S.; Cheng, Y. L.; Zhao, L.; He, C. L.; 
Tang, Z. H.; Chen, X. S. Preparation of photo-cross-linked pH-responsive 
polypeptide nanogels as potential carriers for controlled drug delivery. J. 
Mater. Chem. 2011, 21, 11383–11391.  
[17] Yang, S. C.; Tang, Z. H.; Zhang, D. W.; Deng, M. X.; Chen, X. S. pH and 
redox dual-sensitive polysaccharide nanoparticles for the efficient delivery 
of doxorubicin. Biomater. Sci. 2017, 5, 2169–2178. 
[18] Li, J. M.; Liu, Y.; Li, H. L.; Shi, W.; Bi, X. Z.; Qiu, Q. Q.; Zhang, B.; Huang, 
W. L.; Qian, H. pH-sensitive micelles with mitochondria-targeted and 
aggregation-induced emission characterization: Synthesis, cytotoxicity and 
biological applications. Biomater. Sci. 2018, 6, 2998–3008. 
[19] Li, X.; Li, H.; Yi, W.; Chen, J. Y.; Liang, B. L. Acid-triggered core cross- 
linked nanomicelles for targeted drug delivery and magnetic resonance 
imaging in liver cancer cells. Int. J. Nanomedicine 2013, 8, 3019–3031.  
[20] Wang, X. R.; Liu, G. H.; Hu, J. M.; Zhang, G. Y.; Liu, S. Y. Concurrent 
block copolymer polymersome stabilization and bilayer permeabilization 
by stimuli-regulated “traceless” crosslinking. Angew. Chem. 2014, 126, 
3202–3206.  
[21] Zhang, Z. H.; Yin, L. C.; Tu, C. L.; Song, Z. Y.; Zhang, Y. F.; Xu, Y. X.; Tong, 
R.; Zhou, Q.; Ren, J.; Cheng, J. J. Redox-responsive, core cross-linked 
polyester micelles. ACS Macro Lett. 2013, 2, 40–44.  
[22] Zhang, Y.; Guo, Q.; An, S.; Lu, Y. F.; Li, J. F.; He, X.; Liu, L. S.; Zhang, Y. 
J.; Sun, T.; Jiang, C. ROS-switchable polymeric nanoplatform with stimuli- 
responsive release for active targeted drug delivery to breast cancer. ACS 
Appl. Mater. Interfaces 2017, 9, 12227–12240.  
[23] Hu, X. L.; Chen, X. S.; Wei, J. Z.; Liu, S.; Jing, X. B. Core crosslinking of 
biodegradable block copolymer micelles based on poly(ester carbonate). 
Macromol. Biosci. 2009, 9, 456–463. 
[24] Li, J.; Sun, C. Y.; Tao, W.; Cao, Z. Y.; Qian, H. S.; Yang, X. Z.; Wang, J. 
Photoinduced PEG deshielding from ROS-sensitive linkage-bridged block 
copolymer-based nanocarriers for on-demand drug delivery. Biomaterials 
2018, 170, 147–155.  
[25] Ruan, C. H.; Liu, L. S.; Wang, Q. B.; Chen, X. L.; Chen, Q. J.; Lu, Y. F.; 
Zhang, Y.; He, X.; Zhang, Y. J.; Guo, Q. et al. Reactive oxygen species- 
biodegradable gene carrier for the targeting therapy of breast cancer. ACS 
Appl. Mater. Interfaces 2018, 10, 10398–10408.  
[26] Kramer, J. R.; Deming, T. J. Glycopolypeptides with a redox-triggered 
helix-to-coil transition. J. Am. Chem. Soc. 2012, 134, 4112–4115.  
[27] Han, P.; Li, S. C.; Cao, W.; Li, Y.; Sun, Z. W.; Wang, Z. Q.; Xu, H. P. Red 
light responsive diselenide-containing block copolymer micelles. J. Mater. 
Chem. B 2013, 1, 740–743.  
[28] Liu, J. Y.; Pang, Y.; Zhu, Z. Y.; Wang, D. L.; Li, C. T.; Huang, W.; Zhu, X. 
Y.; Yan, D. Y. Therapeutic nanocarriers with hydrogen peroxide-triggered 
drug release for cancer treatment. Biomacromolecules 2013, 14, 1627–1636. 
[29] Wang, L.; Fan, F. Q.; Cao, W.; Xu, H. P. Ultrasensitive ROS-responsive 
coassemblies of tellurium-containing molecules and phospholipids. ACS 
Appl. Mater. Interfaces 2015, 7, 16054–16060. 
[30] Cao, W.; Gu, Y. W.; Li, T. Y.; Xu, H. P. Ultra-sensitive ROS-responsive 
tellurium-containing polymers. Chem. Commun. 2015, 51, 7069–7071.  
[31] Wang, J. Q.; Zhang, Y. Q.; Archibong, E.; Ligler, F. S.; Gu, Z. Leveraging 
H2O2 levels for biomedical applications. Adv. Biosyst. 2017, 1, 1700084.  
[32] Wang, C.; Wang, J. Q.; Zhang, X. D.; Yu, S. J.; Wen, D.; Hu, Q. Y.; Ye, Y. 
Q.; Bomba, H.; Hu, X. L.; Liu, Z. et al. In situ formed reactive oxygen 
species-responsive scaffold with gemcitabine and checkpoint inhibitor for 
combination therapy. Sci. Transl. Med. 2018, 10, eaan3682.  
[33] Song, X. J.; Feng, L. Z.; Liang, C.; Gao, M.; Song, G. S.; Liu, Z. Liposomes 
co-loaded with metformin and chlorin e6 modulate tumor hypoxia during 
enhanced photodynamic therapy. Nano Res. 2017, 10, 1200–1212.  
[34] Bhaumik, J.; Mittal, A. K.; Banerjee, J.; Chisti, Y.; Banerjee, U. C. 
Applications of phototheranostic nanoagents in photodynamic therapy. 
Nano Res. 2015, 8, 1373–1394.  
[35] Dang, J. J.; He, H.; Chen, D. L.; Yin, L. C. Manipulating tumor hypoxia 
toward enhanced photodynamic therapy (PDT). Biomater. Sci. 2017, 5, 
1500–1511.  
[36] Dolmans, D. E. J. G. J.; Fukumura, D.; Jain, R. K. Photodynamic therapy 
for cancer. Nat. Rev. Cancer 2003, 3, 380–387.  
[37] Sung, S. Y.; Su, Y. L.; Cheng, W.; Hu, P. F.; Chiang, C. S.; Chen, W. T.; Hu, 
S. H. Graphene quantum dots-mediated theranostic penetrative delivery of 
drug and photolytics in deep tumors by targeted biomimetic nanosponges. 
Nano Lett. 2018, 19, 69–81.  
[38] Cui, S. S.; Yin, D. Y.; Chen, Y. Q.; Di, Y. F.; Chen, H. Y.; Ma, Y. X.; 
Achilefu, S.; Gu, Y. Q. In vivo targeted deep-tissue photodynamic therapy 
based on near-infrared light triggered upconversion nanoconstruct. ACS 
Nano 2013, 7, 676–688.  
[39] Idris, N. M.; Gnanasammandhan, M. K.; Zhang, J.; Ho, P. C.; Mahendran, R.; 
Zhang, Y. In vivo photodynamic therapy using upconversion nanoparticles 
as remote-controlled nanotransducers. Nat. Med. 2012, 18, 1580–1585.  
 Nano Res. 2019, 12(5): 999–1008 
 | www.editorialmanager.com/nare/default.asp 
1008 
[40] Qin, W.; Ding, D.; Liu, J. Z.; Yuan, W. Z.; Hu, Y.; Liu, B.; Tang, B. Z. 
Biocompatible nanoparticles with aggregation-induced emission charac-
teristics as far-red/near-infrared fluorescent bioprobes for in vitro and in vivo 
imaging applications. Adv. Funct. Mater. 2012, 22, 771–779.  
[41] Du, X. Q.; Sun, Y.; Zhang, M. Z.; He, J. L.; Ni, P. H. Polyphosphoester- 
camptothecin prodrug with reduction-response prepared via michael addition 
polymerization and click reaction. ACS Appl. Mater. Interfaces 2017, 9, 
13939–13949.  
[42] Hu, J.; He, J. L.; Zhang, M. Z.; Ni, P. H. Folate-conjugated biodegradable 
core cross-linked polyphosphoester micelles for targeted and pH-triggered 
drug delivery. J. Control. Release 2015, 213, e86–e87. 
[43] Yuan, Y. Y.; Liu, J.; Liu, B. Conjugated-polyelectrolyte-based polyprodrug: 
Targeted and image-guided photodynamic and chemotherapy with on- 
demand drug release upon irradiation with a single light source. Angew. 
Chem. 2014, 126, 7291–7296.  
[44] Mock, W. L.; Irra, T. A.; Wepsiec, J. P.; Manimaran, T. L. Cycloaddition 
induced by cucurbituril. A case of Pauling principle catalysis. J. Org. Chem. 
1983, 48, 3619–3620.  
[45] He, Y. Y.; Cheng, G.; Xie, L.; Nie, Y.; He, B.; Gu, Z. W. Polyethyleneimine/ 
DNA polyplexes with reduction-sensitive hyaluronic acid derivatives 
shielding for targeted gene delivery. Biomaterials 2013, 34, 1235–1245.  
[46] Li, F. F.; Li, Y. J.; Zhou, Z. C.; Lv, S. X.; Deng, Q. R.; Xu, X.; Yin, L. C. 
Engineering the aromaticity of cationic helical polypeptides toward 
“self-activated” DNA/siRNA delivery. ACS Appl. Mater. Interfaces 2017, 
9, 23586–23601.  
[47] Lv, S. X.; Wu, Y. C.; Dang, J. Q.; Tang, Z. H.; Song, Z. Y.; Ma, S.; Wang, 
X.; Chen, X S.; Cheng, J. J.; Yin, L. C. Investigation on the controlled 
synthesis and post-modification of poly-[(N-2-hydroxyethyl)-aspartamide]- 
based polymers. Polym. Chem. 2017, 8, 1872–1877.  
[48] Deepagan, V. G.; Kwon, S.; You, D. G.; Van Quy Nguyen; Um, W.; Ko, H.; 
Lee, H.; Jo, D. G.; Kang, Y. M.; Park, J. H. In situ diselenide-crosslinked 
polymeric micelles for ROS-mediated anticancer drug delivery. Biomaterials 
2016, 103, 56–66.  
[49] Zhao, Z.; Wang, J.; Mao, H. Q.; Leong, K. W. Polyphosphoesters in drug 
and gene delivery. Adv. Drug Deliv. Rev. 2003, 55, 483–499.  
[50] Li, Y. J.; Lv, S. X.; Song, Z. Y.; Dang, J. J.; Li, X. D.; He, H.; Xu, X.; 
Zhou, Z. C.; Yin, L. C. Photodynamic therapy-mediated remote control of 
chemotherapy toward synergistic anticancer treatment. Nanoscale 2018, 
10, 14554–14562  
[51] Liu, Y.; Song, N.; Chen, L.; Xie, Z. G. Bodipy@ir(III) complexes assembling 
organic nanoparticles for enhanced photodynamic therapy. Chin. J. Polym. 
Sci. 2018, 36, 417–424. 
 
